AURLUMYN Drug Patent Profile
✉ Email this page to a colleague
When do Aurlumyn patents expire, and when can generic versions of Aurlumyn launch?
Aurlumyn is a drug marketed by Eicos Sci and is included in one NDA.
The generic ingredient in AURLUMYN is iloprost. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iloprost profile page.
Summary for AURLUMYN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | AURLUMYN at DailyMed |
Pharmacology for AURLUMYN
Drug Class | Prostacycline |
Anatomical Therapeutic Chemical (ATC) Classes for AURLUMYN
US Patents and Regulatory Information for AURLUMYN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eicos Sci | AURLUMYN | iloprost | SOLUTION;INTRAVENOUS | 217933-001 | Feb 13, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for AURLUMYN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Bayer AG | Ventavis | iloprost | EMEA/H/C/000474 Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms. |
Authorised | no | no | no | 2003-09-15 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |